株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

リソソーム蓄積症の世界市場:2017年〜2021年

Global Lysosomal Storage Diseases Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 310019
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
SALE 2017年12月31日まで 期間限定キャンペーン
Back to Top
リソソーム蓄積症の世界市場:2017年〜2021年 Global Lysosomal Storage Diseases Market 2017-2021
出版日: 2017年09月18日 ページ情報: 英文 104 Pages
概要

世界のリソソーム蓄積症市場は、2017年から2021年にかけて、7.43%のCAGR(複合年間成長率)で拡大すると予測されています。

当レポートでは、世界のリソソーム蓄積症市場の現状と今後の見通し、薬剤クラス・地域別の動向、市場の発展因子と課題、主なベンダーのプロファイルなどを提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場調査手法

第4章 イントロダクション

  • 市場動向の概略

第5章 リソソーム蓄積症(LSD)の理解

  • イントロダクション

第6章 パイプライン

第7章 市場情勢

  • 市場概要
  • ファイブフォース分析
  • 市場規模・予測
  • リソソーム蓄積症治療の最初の認可薬
  • 市場概要
  • 主な製品

第8章 市場区分:治療法別

  • 酵素補充療法(ERT)
  • 基質還元療法(SRT)
  • シスチン枯渇剤

第9章 地域区分

  • 地域別の市場区分
  • 欧州・中東・アフリカ
  • 南北アメリカ
  • アジア太平洋地域

第10章 意思決定構造

第11章 市場成長因子と課題

第12章 市場動向

第13章 ベンダー情勢

  • 競合シナリオ

第14章 主要ベンダーの分析

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire
  • その他の有望ベンダー

第15章 付録

  • 略語リスト

図表リスト

図表
  • Exhibit 01: Classification of LSDs
  • Exhibit 02: Pipeline snapshot
  • Exhibit 03: Pipeline landscape based on various LSDs
  • Exhibit 04: Key clinical trials
  • Exhibit 05: Global LSDs market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis of the global LSDs market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Global LSDs market segmentation by therapy
  • Exhibit 09: Global LSDs market share by therapy 2016
  • Exhibit 10: Global LSDs ERT market 2016-2021 ($ millions)
  • Exhibit 11: Potential benefits of using ERT for the treatment of various LSDs
  • Exhibit 12: Global LSDs SRT market 2016-2021 ($ millions)
  • Exhibit 13: Global LSDs cystine depleting agents market 2016-2021 ($ millions)
  • Exhibit 14: Global LSDs market share by geography 2016 and 2021
  • Exhibit 15: Global LSDs market revenue by geography 2016-2021
  • Exhibit 16: Global LSDs market share by geography 2016-2021
  • Exhibit 17: Market scenario in EMEA
  • Exhibit 18: LSDs market in EMEA 2016-2021 ($ millions)
  • Exhibit 19: Incentives provided for orphan drugs by EU regulation
  • Exhibit 20: Market scenario in Americas
  • Exhibit 21: LSDs market in Americas 2016-2021 ($ millions)
  • Exhibit 22: Orphan drug development and regulatory challenges
  • Exhibit 23: Incentives provided for orphan drugs by US regulation
  • Exhibit 24: LSDs market in APAC 2016-2021 ($ millions)
  • Exhibit 25: Incentives provided for orphan drugs by Japanese regulation
  • Exhibit 26: Incentives provided for orphan drugs by Australian regulation
  • Exhibit 27: ICD-10 coverage for some of the LSDs
  • Exhibit 28: US FDA filed to approved time: Orphan drugs versus non-orphan drugs and others (median time in months)
  • Exhibit 29: Usefulness of DNA-based testing
  • Exhibit 30: Competitive structure analysis of global LSDs market 2016
  • Exhibit 31: Actelion Pharmaceuticals: Key highlights
  • Exhibit 32: Actelion Pharmaceuticals: Strength assessment
  • Exhibit 33: Actelion Pharmaceuticals: Strategy assessment
  • Exhibit 34: Actelion Pharmaceuticals: Opportunity assessment
  • Exhibit 35: BioMarin: Key highlights
  • Exhibit 36: BioMarin: Strength assessment
  • Exhibit 37: BioMarin: Strategy assessment
  • Exhibit 38: BioMarin Pharmaceuticals: Opportunity assessment
  • Exhibit 39: Genzyme: Key highlights
  • Exhibit 40: Genzyme: Strength assessment
  • Exhibit 41: Genzyme: Strategy assessment
  • Exhibit 42: Genzyme: Opportunity assessment
  • Exhibit 43: Shire: Key highlights
  • Exhibit 44: Shire: Strength assessment
  • Exhibit 45: Shire: Strategy assessment
  • Exhibit 46: Shire: Opportunity assessment

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR14696

About Lysosomal Storage Diseases

Lysosomal storage diseases (LSDs) refer to a group of diseases arising because of the deficiency of lysosomal enzymes, which leads to the accumulation of partially digested or undigested macromolecules inside the cell. LSDs includes progressive diseases with variable ages of onset and clinical symptoms. LSDs are autosomal recessive disorders that are passed on from generation to generation. However, Fabry disease and MPS II are X-linked recessive disorders, which are inherited through mutated alleles on X chromosome.

Technavio's analysts forecast the global lysosomal storage diseases market to grow at a CAGR of 7.43% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lysosomal storage diseases market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Lysosomal Storage Diseases Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire

Other Prominent Vendors

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Chiesi Farmaceutici
  • Greenovation Biotech and FGK Clinical Research
  • Horizon Pharma
  • Leadiant Biosciences
  • Mylan
  • Pfizer
  • Protalix
  • Raptor
  • Recordati
  • Synageva BioPharma
  • Valerion Therapeutics
  • Vtesse

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Expensive treatment regimen for LSDs
  • For a full, detailed list, view our report

Market trend

  • Regulatory assistance in emerging nations
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research methodology

PART 04: Introduction

  • Market outline

PART 05: Understanding LSDs

  • Introduction

PART 06: Pipeline

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by therapy

  • Enzyme replacement therapy (ERT)
  • Substrate reduction therapy (SRT)
  • Cystine depleting agents

PART 09: Market segmentation by geography

  • Geographical segmentation
  • LSDs market in EMEA
  • LSDs market in Americas
  • LSDs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Trends

  • Advent of modern technologies
  • Regulatory assistance in emerging nations
  • Increased R&D activities
  • Increased focus on gene therapy
  • Emergence of immunotherapy
  • Growing public awareness

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire
  • Other Prominent Vendors

PART 15: Appendix

  • List of abbreviations
Back to Top